Abstract
Introduction: Portal vein thrombosis (PVT) increases the risk of variceal rebleeding in liver cirrhosis. However, the strategy for preventing variceal rebleeding in cirrhotic patients with PVT has not been explored. This study aims to evaluate whether transjugular intrahepatic portosystemic shunt (TIPS) or conventional therapy is preferable for the prevention of variceal rebleeding in liver cirrhosis patients with PVT.
Methods and Analysis:
This is a randomized controlled trial comparing the safety and efficacy of TIPS versus conventional therapy (i.e., endoscopic therapy combined with non-selective beta-blockers and anticoagulants) for the prevention of variceal rebleeding in cirrhotic patients with non-tumoral PVT. A total of 50 cirrhotic patients with PVT (thrombus >50% of portal vein lumen occupancy) and a history of variceal bleeding will be stratified according to the Child-Pugh class and degree of PVT, and randomized into the TIPS and Conventional Therapy groups. The primary objective is to compare the incidence of variceal rebleeding between the two groups. The secondary objectives are to compare the overall mortality, variceal rebleeding-related mortality, portal vein recanalization, and complications between the two groups, and to observe the progression of PVT in patients without portal vein recanalization. 
Ethics and Dissemination

Introduction
Variceal bleeding is a common and serious complication of advanced liver cirrhosis [1] [2] [3] . The incidence of a first variceal bleeding within one year is about 12% in cirrhotic patients with gastro-esophageal varices [2] [3] . The incidence of variceal rebleeding within one year is 60%
in cirrhotic patients with a previous history of variceal bleeding, and the mortality from each rebleeding episode is nearly 20% [2] [3] [4] . The presence of portal vein thrombosis (PVT) further increases the incidence of variceal rebleeding in cirrhotic patients [5] .
The efficacies of anticoagulation therapy and transjugular intrahepatic portosystemic shunt (TIPS) for recanalizing PVT in liver cirrhosis have been shown in several case series [6] [7] [8] [9] [10] [11] .
However, the limitations of the two treatment modalities are clear. First, anticoagulation therapy appears to be effective for recanalizing partial PVT rather than complete PVT or cavernous transformation of the portal vein [12] [13] . Second, if anticoagulation therapy was used in cirrhotic patients with a history of variceal bleeding, the risk or severity of bleeding might be further exacerbated [14] [15] . Third, the TIPS technique in the presence of PVT is relatively difficult [16] , and the procedure-related complications are potentially lethal [17] . Due to the absence of randomized controlled studies, no definite treatment algorithm for the management of PVT in liver cirrhosis has been well established in the Baveno V consensus and recent American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of vascular disorders of the liver [18] [19] .
On the other hand, the current therapeutic algorithm for the secondary prophylaxis of variceal bleeding in liver cirrhosis includes non-selective beta-blockers (NSBBs) combined with endoscopic therapy (ET) as the first-line choice of therapy and TIPS as the second-line therapy [2] [3] 18] . This recommendation is mainly because the rate of hepatic encephalopathy is significantly higher in patients undergoing TIPS than in those receiving NSBBs and ET, but the overall survival is not improved [20] [21] . However, the therapeutic algorithm could not be readily extrapolated to cirrhotic patients with PVT.
We hypothesize that TIPS may be superior to conventional therapy for the prevention of variceal rebleeding in liver cirrhosis patients with non-tumoral PVT [22] . Thus, a randomized controlled trial (RCT) is being conducted at our center to explore this issue.
Methods
Study Design
This is a randomized controlled study evaluating TIPS versus conventional therapy (i.e., ET combined with NSBBs and anticoagulants) for the prevention of variceal rebleeding in cirrhotic patients with non-tumoral PVT (Figure 1 ). All subjects who meet the entry criteria will be randomized at a ratio of 1:1 to receive either TIPS or conventional therapy. This study is being performed in the Departments of Liver Disease, Digestive Interventional Radiology, Endoscopy, 5. History of variceal bleeding (all subjects will undergo endoscopy to confirm that the upper gastrointestinal bleeding originates from the esophageal and gastric varices rather than other potential sources).
Exclusion criteria
1. Active variceal bleeding (the time frame of the acute bleeding episode should be 120
hours [18] ).
2. Thrombus occupies <50% of the portal vein lumen.
3. The thrombosed portal trunk is progressed to the fibrotic cord (the patients will be included, if the interventional radiologists consider that the diameter of a collateral vessel is large enough to place a stent [8, 17] 12. Absolute contraindications for TIPS (i.e., congestive heart failure, multiple hepatic cysts, unrelieved biliary obstruction, and severe pulmonary hypertension) [16] .
13. HIV infection (before enrollment, HIV Ag/Ab is measured in all patients).
14. Pregnant or breast-feeding subjects (before enrollment, human chorionic gonadotropin is measured in all female patients).
15. Subjects unable to swallow oral medications.
Informed consent
All relevant information regarding the clinical trial is included in informed consent forms in the Chinese language. Further, the investigators (CH, GH, ZY, and/or XQ) will provide a detailed explanation of this trial to the eligible patients. Informed consent must be signed by all patients or their relatives if the informed consent cannot be signed by the patients themselves. All patients' personal data and medical information will be kept confidential. All patients will be permitted to withdraw from this trial at any time. 
Randomization
After the eligible patients give informed written consent, they will be stratified according to the Child-Pugh class (Child-Pugh class A= 5-6 points, Child-Pugh class B= 7-9 points, Child-Pugh class C= 10-15 points) [23] and the degree of PVT (partial obstruction, complete obstruction, obliterative portal vein) [8, 24] . University.
TIPS group
Patients assigned to the TIPS group will undergo TIPS insertions within 48 hours of randomization. A step-wise TIPS strategy has been described in our previous studies [8, 17, 25] . Because Viatorr covered stents are not approved by the State Food and Drug Administration (SFDA) in the Chinese mainland, Fluency covered stents (Bard Peripheral Vascular, Bard, Inc.) with a diameter of 8 mm and a length of 6-10 cm will be employed in our study. If residual thrombus remains in the distal end of the stent, an indwelling venous catheter will be placed in the confluence of the superior mesenteric vein and splenic vein for local thrombolysis with bolus infusions of urokinase (500,000 units twice a day) for 3 days.
Preoperative and postoperative portosystemic pressure gradients (PSG) will be measured. If the occluded main portal vein or superior mesenteric vein cannot be recanalized or TIPS insertion fails, the patients will be treated with conventional therapy.
After the TIPS insertions, intravenous infusions of heparin (50 mg twice a day) for 5-7 days followed by oral warfarin for 6-12 months will be routinely prescribed at doses that achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction. Intravenous L-ornithine-L-aspartate (20 g once a day) with or without branched-chain amino acids for 4-5 days will be administered for the prevention of portosystemic encephalopathy. Intravenous antibiotics for 4-5 days will be prescribed for the prevention of operation-related infections. If any evidence of shunt dysfunction is observed, TIPS revision by balloon angioplasty and additional stent-placement will be planned, and thereafter, long-term anticoagulation will be prescribed. If the shunt dysfunction cannot be revised, the patients will be treated with conventional therapy.
As we have described previously [8] , shunt dysfunction will be suspected in any one of the Endoscopic screening for recurrent varices is arranged within 1-3 months after variceal obliteration, and a repeat endoscopy is then conducted every 6 months.
NSSBs. Patients assigned to the Conventional Therapy group will receive NSSBs within 5-7 days after endoscopic therapy. According to the AASLD practice guidelines for the management of variceal bleeding [3, 26] , propranolol should be started at a dose of 20 mg twice a day, and is adjusted to the maximum tolerated dose (160 mg twice a day) or until the heart rate is reduced to 55 b.p.m or 25% from baseline.
Anticoagulation. Patients assigned to the Conventional Therapy group will receive
anticoagulants within 2 weeks after variceal obliteration. According to the American College of Chest Physicians (ACCP) guidelines for the management of deep vein thrombosis [27] , intravenous infusions of heparin are initially administered at a dose of 1,000 units per hour for 5 days. Subsequently, oral warfarin should be started at a dose of 2.5 mg once a day, and is adjusted to achieve an INR of up to two times the upper limit of normal or a target INR range of 2 to 3. Oral warfarin therapy will continue for 6-12 months.
NSBBs-induced adverse events include lightheadedness, fatigue, and shortness of breath, while the anticoagulant-induced adverse events include bleeding, thrombocytopenia with or without thrombosis, osteoporosis, skin necrosis, alopecia, hypersensitivity reactions, and hypoaldosteronism. If adverse events are considered mild or moderate, the treatment will be continued or the dose of these drugs will be reduced until they disappear. If adverse events are considered severe or the patients are unable to tolerate these drugs, the treatment will be discontinued. 
Primary objective
To compare the rate of variceal rebleeding between the patients undergoing TIPS and those receiving endoscopic therapy combined with NSSBs and anticoagulants.
Secondary objectives
1. To compare the rate of overall death and variceal bleeding-related death between the two groups (subgroup analyses will be performed according to the Child-Pugh class and grade of PVT).
2. To compare the rate of portal vein recanalization between the two groups (subgroup analyses will be performed according to the Child-Pugh class and grade of PVT).
3. To compare the rate of procedure-related complications between the two groups.
4. To compare the rate of hepatic encephalopathy after treatment between the two groups.
5. To evaluate the rate of shunt dysfunction in TIPS group.
6. To observe the progression of PVT in patients without portal vein recanalization.
Data collection
Paper case report forms have been designed for data collection by one investigator (QX).
Upon enrollment, the following data will be collected:
1. Demographic characteristics (sex and age).
2. Physical examination parameters (blood pressure, heart rate, height, weight, shifting dullness, hepatomegaly, and splenomegaly). 
Electrocardiogram.
6. Anteroposterior chest radiographs.
7. Abdominal CDUS (liver, spleen, grade of ascites [28] , and the extension and degree of PVT [24] ).
8. Abdominal CT scans (liver, spleen, grade of ascites, and the extension and degree of PVT).
9. Upper gastrointestinal endoscopy (the location, form, and diameter of the varices and red color signs).
10. Child-Pugh [23] and Model for End-stage Liver Disease (MELD) scores [29] .
As the patients are allocated into the TIPS group, the following data will be collected:
1. The overall duration of the TIPS procedure.
2. Approaches used for the percutaneous puncture of the portal vein (transjugular, trans-hepatic, and trans-splenic approaches). 4. The number of coils if embolization is performed.
5. The number of TIPS stents.
6. Whether local thrombolysis is performed after stent placement.
7. The PSG before and after TIPS.
8. TIPS procedure-related complications (i.e., hepatic capsule perforation, stent displacement).
9. Whether TIPS revision is performed.
10. The number, duration, and methods (additional stent-placement and/or balloon angioplasty) of TIPS revision(s) if TIPS revision is performed.
As the patients are allocated into the Conventional Therapy group, the following data will be collected:
1. The overall duration of endoscopic therapy.
2. The number of sessions required to eradicate the varices.
3. The methods of endoscopic therapy (i.e., variceal ligation, sclerotherapy, and cyanoacrylate glue injection).
4. The number of bands and volume of sclerosant and glue.
5. Endoscopic therapy-related complications.
6. The dose of propranolol used for adequate beta blockade.
7. Heart rate at the time of adequate beta blockade.
8. Whether propranolol is discontinued.
9. The dose of warfarin used as the target INR is achieved.
10. Whether warfarin is discontinued.
Adverse events of propranolol and warfarin.
A regular follow-up flow chart will be established (Figure 2) . The grade of varices will be evaluated by endoscopy. The Child-Pugh and MELD scores will be calculated. The extension and degree of PVT will be evaluated by abdominal CDUS and CT scans. According to previous studies [7, [30] [31] , portal vein recanalization is considered complete if the portal vein trunk, superior mesenteric vein, and splenic vein are patent; portal vein recanalization is considered partial if the degree of thrombosis within the portal vein trunk is decreased.
Additionally, all enrolled patients will have telephone follow up with one investigator (WZ)
regarding their conditions and drug use every week in the first month and once per month thereafter.
As hepatic encephalopathy occurs, the following data will be collected:
1. The number of episodes of hepatic encephalopathy.
2. The starting time and duration of every episode of hepatic encephalopathy.
The grade of every episode of hepatic encephalopathy according to the West Haven
Criteria [32] .
4. The treatment and outcome of every episode of hepatic encephalopathy.
As shunt dysfunction occurs, the following data will be collected: 2. The starting time and duration of every episode of shunt dysfunction.
3. The diagnosis, treatment, and outcome of every episode of shunt dysfunction.
As variceal bleeding recurs, the following data will be collected:
1. The number of variceal rebleeds.
2. The starting time and duration of every episode of variceal rebleeding.
3. The causes of every episode of variceal rebleeding.
4. The treatment and outcome of every episode of variceal rebleeding.
As any patient dies, the following data will be collected:
1. The time of death after enrollment.
2. The cause of death.
Sample size calculation
No study has yet compared the outcome between cirrhotic patients with PVT receiving TIPS and those receiving conventional therapy. The sample size was determined on the basis of the results of 12 RCTs in which the rate of variceal bleeding was compared between cirrhotic patients without PVT treated by TIPS and endoscopic therapy ( Table 1 ) [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . The pooled rates of variceal rebleeding are estimated to be 20.0% and 43.4% in the TIPS and endoscopic therapy groups, respectively. Notably, bare stents were employed in these 12 RCTs, but covered stents will be used in our study.
Because the rate of shunt dysfunction is lower in patients with covered stents than in those with bare stents [45] [46] , the rate of variceal rebleeding should be lower in the patients allocated to the TIPS group in our study. On the other hand, given that the rate of variceal bleeding is significantly aggravated by the presence of portal vein thrombosis [5] , the rate of variceal rebleeding might be higher in patients allocated to the Conventional Therapy group in our study. Thus, we presume that the rates of variceal rebleeding will be 10% and 45% in TIPS and Conventional Therapy groups, respectively. Considering a type I (α) error of 5%, a type II
(1-β) error of 20%, and a dropout rate of 10%, the total number of patients to be recruited is 50.
Statistical analysis
All data will be analyzed on the intention-to-treat population. Continuous variables will be summarized as the mean values (± standard errors) or the median values (ranges), and will be compared using the independent sample t-test or one-way analysis of variance (ANOVA).
Categorical variables will be expressed as frequencies, and will be compared using the Chi-square test or Fisher's exact test. Cumulative risks will be assessed with Kaplan-Meier curves, and will be compared using the log-rank test. The independent predictors for variceal rebleeding, death, and variceal bleeding-related death will be calculated using the Cox regression model. Two-tailed p-values <0.05 will be considered statistically significant. All statistical calculations will be performed using SPSS 12.0 (Chicago, Illinois, USA) and SAS 8.1
(Cary, North Carolina, USA).
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Discussion
Study implications
PVT increases the rate of variceal rebleeding and mortality in cirrhotic patients [5, 47] , thereby negatively changing the natural history of advanced liver cirrhosis [48] . However, no randomized controlled studies have evaluated which treatment modality is preferable to prevent variceal rebleeding in cirrhotic patients with PVT. This study is the first RCT to explore the efficacy of TIPS and conventional therapy for the prevention of variceal rebleeding in such patients. Survival and portal vein recanalization will be compared between patients treated by TIPS and conventional therapy. If TIPS is superior to conventional therapy, TIPS might be recommended as the first-line therapy in these patients. This study will also provide information regarding the natural history of cirrhotic patients with PVT that cannot be recanalized.
Study limitations
First, cirrhotic patients with PVT are our target population. However, the sample size was calculated according to the previous results observed in cirrhotic patients without PVT.
Therefore, the number of patients to be recruited in our study may be inadequate. Second, because the primary endpoint is variceal rebleeding, the power calculation is primarily based on a difference in the rate of variceal rebleeding between both groups. Thus, the data regarding mortality should not be overemphasized. Third, this study is being conducted in a single center with TIPS technique experience. Accordingly, our findings might not be promptly generalized to other centers with less experience. However, it should be noted that an increasing trend in the number of PVT patients undergoing TIPS has been clearly identified [17] . Fourth, the most common cause of liver cirrhosis is hepatitis B virus in China, while it is alcohol abuse in Western countries. The difference in the etiology of liver cirrhosis might influence the application of our findings in Western countries. Fifth, "TIPS rescue" therapy may potentially increase the survival of patients assigned to the Conventional Therapy group. Thus, the difference in the mortality between the two treatment modalities cannot be truly reflected.
Sixth, we did not clearly define the maximum interval from the last episode of variceal bleeding to our randomization. Considering that a longer interval might be associated with a better survival, the absence of the threshold might produce the bias of patient selection. Certainly, this selection bias might be minimized due to the nature of randomization. 
Ethical approval
Trial registration
This study was registered at ClinicalTrials.gov on March 29, 2011 . The trial registration number is NCT01326949.
Trial status
The first patient was recruited into our study on June 4, 2011. A total of 29 patients were Therapy groups, respectively).
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